Instem Acquires Leadscope; Prominent Provider of In Silico Safety Assessment Solutions
Summary
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Instem, a leading provider of IT solutions to the global life sciences market, announced today that it has acquired Leadscope, Inc. as part of its mission to further consolidate and harmonize key application areas that are helping customers streamline and accelerate their research and development processes. Leadscope is known for its advanced informatics and prediction technology, along with database solutions, that help organizations effectively unlock valuable knowledge contained in both public and proprietary sources of research data. The industry continues to evaluate the practicality of high-cost animal testing combined with the need to assess the safety of substances in a limited timeframe amidst a competitive environment; including the need to innovate new chemicals and products that satisfy ever-changing market demands. The ICH M7 guideline describes a consistent approach, that can be utilized from preclinical through to final submissions, to identify, categorize, and control DNA reactive (mutagenic) impurities in pharmaceutical products to limit potential carcinogenic risk. Going forward, combining Instem and Leadscope’s technologies will provide unique and more seamless solutions for the integration of public data and proprietary information to support the discovery and development of pharmaceuticals and other chemical products.
Classifications
AskAI Classifications
LabelsLinked Companies
